Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment

NCT06796062 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT06796062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06796062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Recruiting
Start date
December 17, 2025
Completion date
February 28, 2029
Enrollment
480 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

opioid use disorder